Botulinumtoxin A – was gibt es Neues?

Zusammenfassung

Nach über 20 Jahren Anwendung von Botulinumtoxin A in der Ästhetischen Medizin gibt es wenig neue Herausforderungen. Die Standardindikationen, die Standardinjektionspunkte und die Dosierungen sind klar und ermöglichen eine wirksame und sichere Behandlung unserer Patienten. Um die Behandlungszufriedenheit kontinuierlich zu verbessern, müssen individuelle Wünsche und die jeweilige anatomische Konstellation im Injektionsplan berücksichtig werden. Mit jedem neuen Patienten wachsen unsere Erfahrungen. Wir sehen mehr, verstehen mehr und lernen unsere Patienten besser zu behandeln. Mit den neuen Toxinen aus Asien und den vorverdünnten Toxinen wird sich der Markt für Botulinumtoxine in den nächsten Jahren beleben. Die Behandlungen mit Botulinumtoxin werden mit großer Wahrscheinlichkeit durch das vermehrte Angebot der Botulinumtoxine günstiger für unsere Patienten werden.

Abstract

After 20 years of botulinum toxin in Aesthetic Medicine there are not many remaining challenges. The standard indications, injection points and dosages are well known and enable an efficacious and safe treatment of our patients. To increase patient satisfaction with the treatment further individual wishes and anatomical constellations need to be taken into consideration when designing the injection plan. With every new patient, we gain experience. We see more, we understand more and by this we learn to treat our patients better. With the new toxins from Asia and the prediluted toxins the present markets will see some changes. With the growing number of botulinum toxins, it is quite reasonable to predict that treatment with botulinum toxins will become more affordable for our patients.

• Literatur

• 1 Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21
• 2 De Maio M, Rzany B. Botulinum toxin in Aesthetic Medicine. Heidelberg: Springer; 2007
• 3 Sommer B, Bergfeld D, Sattler G. Consensus recommendations on the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol Ges 2007; 58 (Suppl. 01) S1-S29
• 4 Rzany B, Fratila AA, Fischer TC. et al. Recommendations for the best possible use of botulinum neurotoxin type a (speywood units) for aesthetic applications. J Drugs Dermatol 2013; 12: 80-84
• 5 Won CH, Kim HK, Kim BJ. et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol 2015; 54: 227-234
• 6 Kim JE, Song EJ, Choi GS. et al. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg 2015; 135: 732-741
• 7 Ascher B, Kestemont P, Boineau D. et al. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial. Aesthet Surg J 2017; [Epub ahead of print]. DOI: 10.1093/asj/sjw272.
• 8 Kane MA, Brandt F. Reloxin Investigational Group. et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124: 1619-629
• 9 Kerscher M, Rzany B, Prager W. et al. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study. Dermatol Surg 2015; 41: 1149-1157
• 10 Sneath J, Humphrey S, Carruthers A. et al. Injecting botulinum toxin at different depths is not effective for the correction of eyebrow asymmetry. Dermatol Surg 2015; 41 (Suppl. 01) S82-S87
• 11 Allen SB, Goldenberg NA. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Dermatol Surg 2012; 38: 867-870
• 12 Sezgin B, Ozel B, Bulam H. et al. The Effect of Microneedle Thickness on Pain During Minimally Invasive Facial Procedures: A Clinical Study. Aesthet Surg J 2014; 34: 757-765
• 13 Steinsapir KD, Groth MJ, Boxrud CA. Persistence of Upper Blepharoptosis After Cosmetic Botulinum Toxin Type A. Dermatol Surg 2015; 41: 833-840
• 14 Fabbri M, Leodori G, Fernandes RM. et al. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res 2016; 29: 105-117